AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04157400 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proprioception Testing During Stimulation
Description: Step 3: Proprioception testing~The research team will investigate the perceived change in knee joint angle and direction of movement reported by the subject in a Threshold to Detect Passive Movement (TTDPM). The TTDPM protocol will begin with the subject sitting in the Biodex testing seat, with the non-tested leg hanging freely and the tested leg strapped to the rotating arm of the dynamometer at the lower shank. The subject will be blinded as to the mode and intensity of stimulation: HFBS, LFTS, or no stim. The TTDPM will consist of at least 10 trials for each stimulation condition chosen based on SCM outcomes. The subject has control of a kill-switch that immediately halts movement of the rotating arm, which is to be activated once the subject perceives movement OR if the subject begins to feel any pain or discomfort throughout the task.
Study NCT04157400 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gait Analysis During Stimulation
Description: Step 4: Body weight support and treadmill (BWST) testing~Similar to step 2, LFTS and HFBS patterns will be compared by systematically testing each individual contact on the paddle while investigating for changes in stepping speed, pattern and EMG moduling complexity. Regarding EMG module analysis, muscle activity will be recorded bilaterally via surface EMG from lower extremity musculature. Furthermore, subjects will also have active LED markers placed over their clothes in order to track whole body kinematics throughout this portion of the study.~To optimize capture of steady state data on the treadmill, each subject will walk for approximately 10 sec prior to the 30 sec of data collection (40 sec per trial). This will allow capture of at least 10 consecutive steady state gait cycles (depending on cadence) per each amplitude selection for each stimulation delivery technique, which will be defined by parameters found during walking SCM.
Study NCT00045773 — intervention group
Intervention type: DRUG
Intervention: Sertraline
Description: 50 - 200mg, once per day for 12 weeks.
Study NCT03953755 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tricuspid valve repair
Description: Tricuspid valve repair
Study NCT01585155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-650
Description: TA-650 will be intravenously infused at 5 mg/kg as an induction regimen at Weeks 0, 2, 6. For subjects who meet the responder criteria, TA-650 will be administered at 8-week intervals thereafter until week 22.
Study NCT00659555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib eye drops
Description: Pazopanib will be administered as eye drop solution via topical ocular route. Pazopanib eye drops will be available as white, colorless solution.
Study NCT00659555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconozole tablets
Description: Ketoconozole will be administered as tablets via oral route. Ketoconozole tablets will be present as white, rounded, scored tablets
Study NCT00577317 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Management of Therapy Complications
Description: Receive Flexitouch home maintenance therapy
Study NCT00577317 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03045939 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: cervical ripening device
Description: insertion of the double balloon device for 12 hours (standard care) vs 6 hours, following oxytocin IV infusion according local protocol guidelines as mentioned above
Study NCT03045939 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cervical ripening device
Description: insertion of the double balloon device for 12 hours (standard care) vs 6 hours, following oxytocin IV infusion according local protocol guidelines as mentioned above
Study NCT00925353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4% lidocaine gel
Description: 1 ounce 4% lidocaine gel on skin of breasts and chest wall for 1 hour under occlusion, then removed with warm water
Study NCT02729064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humulin R
Description: Study subjects will receive intranasal insulin (Humulin R) via a metered nasal dispenser.
Study NCT02729064 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Study subjects will receive intranasal placebo (normal saline) via a metered nasal dispenser.
Study NCT00767572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: Atorvastatin 80mg daily vs. placebo daily X 12 weeks, then 4 week washout period, then cross over groups to complete another 12 weeks. (Total study time is 28 weeks (12+4+12)
Study NCT00767572 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: atorvastatin 80mg daily vs. placebo daily X 12 weeks, then 4 week washout, then cross over groups X 12 weeks. Total study time is 28weeks (12+4+12).
Study NCT00583310 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-based lifestyle counseling
Description: Four 30-minute telephone sessions including education and behavioral counseling strategies that have been shown to be effective in promoting behavior change and reducing blood pressure.
Study NCT01655316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil
Study NCT04037124 — intervention group
Intervention type: PROCEDURE
Intervention: Cervical procedure
Description: simple hysterectomy, radical hysterectomy or fertility sparing surgery
Study NCT01831895 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MobiusHD™
Description: Implant that is placed in the carotid sinus to control hypertension.
Study NCT02779140 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NTM-1632
Description: Monoclonal antibody mixture of XB10, XB18, and XB23
Study NCT02779140 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT04645563 — intervention group
Intervention type: OTHER
Intervention: Sending thorax ct video images via smartphone applications
Description: Video images of the patients will be sent via smartphone application to infectious disease specialist for consulting.
Study NCT04892732 — intervention group
Intervention type: DRUG
Intervention: Budesonide
Description: Budesonide dispensing claim is used as the reference group.
Study NCT04892732 — intervention group
Intervention type: DRUG
Intervention: Budesonide-Formoterol
Description: Budesonide-Formoterol dispensing claim is used as the exposure group.
Study NCT04426097 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical Vagal Blockade
Description: Cervical Vagal Blockade with 0.5 % ropivacaine 2.5 ml and 2% xylocaine 2.5 ml
Study NCT04426097 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Without Blockade
Description: Without Blockade
Study NCT01283100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1349572
Description: 50mg once every 24 hours for 7 days
Study NCT01283100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2248761
Description: 200 mg once every 24 hours for 7 days
Study NCT04083560 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vit B12
Description: Vitamin B12 250mcg
Study NCT04083560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vit B12
Description: Vitamin B12 250mcg
Study NCT00847600 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pregnenolone
Description: 50 mg, caps.
Study NCT00847600 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: caps
Study NCT00295165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim (Leukine)
Description: Sargramostim 6 mcg/kg subcutaneously once daily
Study NCT00295165 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneously once daily
Study NCT01807533 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-centered intervention program
Description: This program was in-hospital intervention, after-discharge intervention, and neonatal follow-up. Five sessions of in-hospital intervention emphasized in the parental involvements with modulation of the NICU, a teaching of child developmental skills, feeding support, massage, interactional activities, child developmental skills, parent support and education, and transition home preparation. The 7-session after-discharge intervention consisted of 4 clinic visits and 3 home visits with specific care in modulation of home environment, teaching of child developmental skills, feeding support, teaching of interactional activities, and parent support and education
Study NCT01807533 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual care intervention program
Description: This program was in-hospital intervention, after-discharge consultation, and neonatal follow-up. Five sessions of in-hospital intervention emphasized in the parental involvements with modulation of the NICU, a teaching of child developmental skills, feeding support, massage, interactional activities, child developmental skills, parent support and education, and transition home preparation. The after-discharge service was provided 7-phone calls for the general health consultation.
Study NCT00349362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Sustanon- 200mg intramuscular testosterone
Study NCT00349362 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline
Description: Saline intramuscular injection every two weeks
Study NCT01456572 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: ensure plus
Description: 17 % protein, 30 % fat and 53 % carbohydrate; 1 kcal/mL
Study NCT01456572 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ensure plus
Description: 17 % protein, 30 % fat and 53 % carbohydrate; 1 kcal/mL
Study NCT01456572 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: standardized test meal
Description: scrambled eggs, two slices of whole wheat bread, 200 mL of milk and labeled with 13C-octanoic acid
Study NCT01456572 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: standardized test meal
Description: scrambled eggs, two slices of whole wheat bread, 200 mL of milk and labeled with 13C-octanoic acid
Study NCT01413087 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological/Vaccine: BC-819
Description: Post screening and prior to randomization, all patients will receive gemcitabine by IV infusion at a dose of 1000mg/m2 once weekly for four weeks. They may also enter the study if they received up to 4 doses of gemcitabine before entering the study. In this case, they will be randomized immediately provided there is no evidence of disease progression.~After randomization patients will receive 6 weekly IV infusions of gemcitabine at a dose of 1000mg/m2 + 7 intratumoral injections of BC-819 (8 mg or 12 mg according to allocations by randomization)
Study NCT05637359 — intervention group
Intervention type: DEVICE
Intervention: Tracked ultrasound measurement
Description: Participation in the study will not involve additional visits to the hospital or additional CT scans for the included patients. For this experiment, 2D ultrasound images are obtained using an ultrasound transducer linked to the electromagnetic navigation system, which is already in place for the navigation at the operating room. After anesthesia and in parallel to the final preparations of the patient, two percutaneous ultrasound measurements of the pelvic bone are performed and recorded. The first measurements are performed in Trendelenburg patient position and the second measurements in supine patient position. When preparations are finished, normal workflow is continued, including the standard Cone Beam CT acquisition required for the navigation and sterile draping of the patient.~The acquired ultrasound scans will be analyzed post-operatively and offline. This measurement has no impact on the (navigated) surgical procedure itself.
Study NCT04613544 — intervention group
Intervention type: DEVICE
Intervention: Voice Assist Arrhythmia Monitoring (VAAM)
Description: application flag the potential occurrence of irregular heart rhythms suggestive of atrial fibrillation (AF) and notify to further investigate the occurrence of the suspected AF episode by prompting user to initiate ECG test to confirm.
Study NCT01696903 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreaticojejunostomy technique
Description: The anastomosis between jejunum and remnant pancreas has a pivotal impact on the incidence of postoperative pancreatic fistula. by this novel technique the remnant pancreas is intubated into the jejunum without extensive manipulation.
Study NCT00636805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron (Aloxi) and Dexamethasone
Description: single i.v. , dose of palonosetron 0.25 mg, and 10mg dexamethasone infused over 15 min, administered 30 min before the first dose Irinotecan and Bevacizumab chemotherapy.
Study NCT02296736 — intervention group
Intervention type: RADIATION
Intervention: Computerised tomography (CT) scan
Description: Retrospective review of CT scans
Study NCT03609892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berberine
Description: Berberine-amoxicillin quadruple therapy group: given for 14 days at a dose of berberine 100 mg 3 tablets TID, amoxicillin 500 mg 2 capsules BID ，esomeprazole 20 mg BID, ,and Bismuth 100 mg 2 capsules BID.
Study NCT03609892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Berberine-amoxicillin quadruple therapy group: given for 14 days at a dose of Amoxicillin 500 mg 2 capsules BID plus berberine 100 mg 3 tablets TID, esomeprazole 20mg 1tablet BID, and bismuth 100 mg 2 capsules BID
Study NCT03609892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Berberine-amoxicillin quadruple therapy group: given for 14 days at a dose of Esomeprazole 20mg 1 tablet BID plus berberine 100 mg 3 tablets TID,amoxicillin 500 mg 2 capsules BID, and bismuth 100 mg 2 capsules BID
Study NCT03609892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth
Description: Tetracycline-furazolidone containing quadruple therapy group: given for 14 days at a dose of Tetracycline 250mg 2 capsules TID plus furazolidone 100mg 1 tablets BID，esomeprazole 20 mg 1 tablets BID and bismuth 100 mg 2 capsules BID
Study NCT03609892 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracycline
Description: Tetracycline-furazolidone containing quadruple therapy group: given for 14 days at a dose of Tetracycline 250mg 2 capsulesTID plus furazolidone 100mg 1 tablets BID，esomeprazole 20 mg 1 tablets BID and bismuth 100 mg 2 capsules BID
Study NCT03609892 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furazolidone
Description: Tetracycline-furazolidone containing quadruple therapy group: given for 14 days at a dose of furazolidone 100mg 1 tablets BID plus Tetracycline 250mg 2 capsulesTID，esomeprazole 20 mg 1 tablets BID and bismuth 100 mg 2 capsules BID
Study NCT03609892 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: Tetracycline-furazolidone containing quadruple therapy group: given for 14 days at a dose of esomeprazole 20 mg 1 tablets BID plus Tetracycline 250mg 2 capsules TID, furazolidone 100mg 1 tablets BID， and bismuth 100 mg 2 capsules BID
Study NCT03609892 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth
Description: Tetracycline-furazolidone containing quadruple therapy group: given for 14 days at a dose of bismuth 100 mg 2 capsules BID plus Tetracycline 250mg 2 capsules TID ，furazolidone 100mg 1 tablets BID and esomeprazole 20 mg 1 tablets BID
Study NCT00542542 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Paravertebral Block
Description: Paravertebral block given as a bolus injection into the paravertebral space.
Study NCT00542542 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: 2-2.5 mg/kg IV over 1-4 hours during surgery.
Study NCT00542542 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: 50-250 mcg IV over 1-4 hours during surgery.
Study NCT00542542 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Ropivacaine given by injection into the paravertebral space along the spinal canal.
Study NCT00542542 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: 0.08 mg/kg IV over 1-4 hours during the surgery.
Study NCT02169544 — intervention group
Intervention type: DRUG
Intervention: Abatacept
Study NCT01743391 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Office-hysteroscopy with biopsy
Study NCT00538317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tirofiban
Description: bolus of 25 µg/kg lasting 3 minutes then 18h to 24h perfusion of 0.15 µg/kg/min
Study NCT00538317 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tirofiban
Description: bolus of 25 µg/kg lasting 3 minutes then 18h to 24h perfusion of 0.15 µg/kg/min
Study NCT04061460 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: mechanical plaque control
Description: supra and sub gingival debridment ( plaque control)
Study NCT02038556 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behaviorial therapy -Insomnia
Study NCT00566605 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Penetrating keratoplasty with IntraLase
Description: penetrating keratoplasty with femtosecond laser shaped incisions- IntraLase TM (IntraLase Enabled Keratoplasty \[IEK\])
Study NCT00566605 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Penetrating keratoplasty with vacuum trephine
Description: Group 2 - penetrating keratoplasty with vacuum trephine
Study NCT04425070 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: ICE [ifosfamide+carboplatin+etoposide]
Description: • Combined with ICE chemotherapy regimen:~* Ifosfamide: 5 g/m2, continuous intravenous (iv) infusion (mesna 5 g/m2 synchronously iv infusion for rescue), on Day 2;~* Carboplatin: with concentration-area under time curve (AUC)=5 (highest concentration to 800 mg), iv infusion, on Day 2;~* Etoposide l00 mg/m2, iv infusion, on Days 1-3;~* ATG-010 60 mg/once, oral, on Days 4 and 11. After the treatment with combination chemotherapy, the patients will continue to receive maintenance treatment of ATG-010 60 mg/once per week (QW).
Study NCT01297153 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intraocular Lens (Acrysof IOL)
Description: IOL fixation, material and size are important determinants of immediate and long-term outcome. In-the-bag fixation is the most preferred site of IOL implantation.
Study NCT01297153 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: No IOL
Description: No IOL will be implanted in these eyes
Study NCT04425070 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: GEMOX [gemcitabine+oxaliplatin]
Description: • Combined with GEMOX chemotherapy regimen:~* Gemcitabine 1000 mg/m2, iv infusion, on Days 1 and 8;~* Oxaliplatin 130 mg/m2, iv infusion, on Day 1;~* ATG-010 60 mg/once, oral, on Days 2 and 9. After the treatment with combination chemotherapy, the patients will continue to receive maintenance treatment of ATG-010 60 mg/once per week (QW).
Study NCT04425070 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab will be administered intravenously at a fixed dose of 2 0 0 mg every 3 weeks on Day 1 of each cycle
Study NCT00944710 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine
Description: Weekend atropine 1%
Study NCT00944710 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Plano lens
Description: plano lens over the sound eye
Study NCT00766324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PHA-739358
Description: 6-hr IV infusion weekly for 3 consecutive weeks in a 4-week cycle
Study NCT00766324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PHA-739358
Description: 24-hr IV infusion every 2 weeks in a 4-week cycle
Study NCT01939314 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Bupivavaine Delivered by the Tx 360 Device to the Sphenopalatine Ganglion
Study NCT01939314 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline Delivered by the Tx 360 Device to the Sphenopalatine Ganglion
Study NCT03728062 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation
Description: Guided mindfulness meditation focused on breath sensations, thoughts and emotions.
Study NCT03728062 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: Cardio exercise at gym like rowing, eliptical, cycling, or running outside.
Study NCT00735007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebif® New Formulation (RNF) using RebiSmartTM
Description: RNF 44 mg, 3 times a week by subcutaneous injection.
Study NCT04054544 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gluten powder 4g
Description: Gluten powder 4g oral BID
Study NCT00830765 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone (OHP17)
Description: 100mg of OHP17 or comparable amount of placebo administered by IM injection weekly until either 34 weeks' gestation or delivery has been achieved, whichever occurs first.